東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Risk Management in Biopharmaceutical...

Ma, Yao.

FindBook

Google Book

Amazon

博客來

Risk Management in Biopharmaceutical Supply Chains.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Risk Management in Biopharmaceutical Supply Chains./
作者:	Ma, Yao.
面頁冊數:	123 p.
附註:	Source: Dissertation Abstracts International, Volume: 75-01(E), Section: B.
Contained By:	Dissertation Abstracts International75-01B(E).
標題:	Operations research. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3593646
ISBN:	9781303368646

Risk Management in Biopharmaceutical Supply Chains.
Ma, Yao.

Risk Management in Biopharmaceutical Supply Chains. - 123 p.

Source: Dissertation Abstracts International, Volume: 75-01(E), Section: B.

Thesis (Ph.D.)--University of California, Berkeley, 2011.

This item is not available from ProQuest Dissertations & Theses.

Biopharmaceutical supply chains present considerable complexity issue for the formulation of optimal plans due to significant uncertainty in the supply chain. The primary goal of biopharmaceutical supply chain planning is to provide reliable supply to patients while coping with various supply chain risks. In chapter 1 first I discuss the key elements and basic characteristics of the biopharmaceutical supply chain . Then I present the major challenges in biopharmaceutical supply chain planning and divide them into two main categories: deterministic complexity problems and stochastic uncertainty problems. In the end of chapter 1 I briefly discuss the most recent work in solving the deterministic complexity problems.

ISBN: 9781303368646Subjects--Topical Terms:

547123
Operations research.

Risk Management in Biopharmaceutical Supply Chains.
LDR:03736nmm a2200313 4500 001 2067273
005 20160226101925.5
008 170521s2011 ||||||||||||||||| ||eng d
020 $a 9781303368646
035 $a (MiAaPQ)AAI3593646
035 $a AAI3593646
040 $a MiAaPQ $c MiAaPQ
100 1 $a Ma, Yao. $3 3182113
245 1 0 $a Risk Management in Biopharmaceutical Supply Chains.
300 $a 123 p.
500 $a Source: Dissertation Abstracts International, Volume: 75-01(E), Section: B.
500 $a Adviser: Robert Leachman.
502 $a Thesis (Ph.D.)--University of California, Berkeley, 2011.
506 $a This item is not available from ProQuest Dissertations & Theses.
520 $a Biopharmaceutical supply chains present considerable complexity issue for the formulation of optimal plans due to significant uncertainty in the supply chain. The primary goal of biopharmaceutical supply chain planning is to provide reliable supply to patients while coping with various supply chain risks. In chapter 1 first I discuss the key elements and basic characteristics of the biopharmaceutical supply chain . Then I present the major challenges in biopharmaceutical supply chain planning and divide them into two main categories: deterministic complexity problems and stochastic uncertainty problems. In the end of chapter 1 I briefly discuss the most recent work in solving the deterministic complexity problems.
520 $a The planning of biopharmaceutical supply chain operations faces risks from various sources. These include customer demand fluctuations, regulatory requirement changes, long quality assurance cycle time, etc. In chapter 2, I review the major risks in biopharmaceutical supply chain and current practice to hedge against these risks. The impact of these risks is evaluated in terms of a cumulative supply and demand perspective. Furthermore I analyze two main risk mitigation tools in supply chain risk management: safety stock and safety time. Then I use simulation to show that safety stock is a preferred approach for risk mitigation in biopharmaceutical supply chains.
520 $a In chapter 3, first I focus on stochastic lead time risk and discuss conventional as well as crossover based approaches for safety stock planning. Also I demonstrate the benefit of a proposed approach to safety stock planning with numerical examples and simulation. Then the proposed model is extended to consider batch rejection risk and excursion risk. Batch rejection risk represents the possibility that a batch fails to meet regulatory requirements. The excursion risk reflects potential major disruptions in biopharmaceutical supply chain. Examples of such events include contamination of the production facility, earthquake, etc. These three risks cover most of the major uncertainties in biopharmaceutical supply chain. The model determines the necessary safety stock level to prevent stock outs given these risks as a function of the target service level. In chapter 4, I discuss the implementation of the proposed model in a multi-echelon biopharmaceutical supply chain. Also I use sensitivity analysis to evaluate the impact of improving key supply chain parameters. Then the model is applied to determine the stock level supplying a regional market of an actual biopharmaceutical supply chain and significant potential savings are demonstrated. In the end I identify a few important potential research problems in biopharmaceutical supply chain management.
590 $a School code: 0028.
650 4 $a Operations research. $3 547123
650 4 $a Industrial engineering. $3 526216
690 $a 0796
690 $a 0546
710 2 $a University of California, Berkeley. $b Industrial Engineering and Operations Research. $3 2096281
773 0 $t Dissertation Abstracts International $g 75-01B(E).
790 $a 0028
791 $a Ph.D.
792 $a 2011
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3593646